Niraparib and Abiraterone

Brand names: Akeega · Active ingredient: Niraparib Tosylate Monohydrate, Abiraterone Acetate

In short: AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA2-mutated ( BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC). AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected del

Forms & strengthsTablets 50 mg niraparib/500 mg abiraterone acetate: yellowish orange to yellowish brown, oval, film-coated tablets debossed with "N 50 A" on one side and plain on the other side. …
LabelJanssen Biotech, Inc.
Label updatedDec 22, 2025

What is Niraparib and Abiraterone used for?

AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious

BRCA2-mutated (

BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC).

AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious

BRCA-mutated (

BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

Select patients for therapy based on an FDA-approved test for AKEEGA

.

Niraparib and Abiraterone dosage

Select patients for the treatment of mCSPC with AKEEGA based on the presence of a

BRCA2 gene alteration

.

Select patients for the treatment of mCRPC with AKEEGA based on the presence of a

BRCA gene alteration

.

Information on FDA-approved tests is available at: http://www.fda.gov/CompanionDiagnostics.

BRCA2-mutated (

BRCA2m) Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

The recommended dosage of AKEEGA is 200 mg niraparib/1,000 mg abiraterone acetate orally once daily in combination with 5 mg prednisone once daily until disease progression or unacceptable toxicity.

BRCA-mutated (

BRCAm) Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The recommended dosage of AKEEGA is 200 mg niraparib/1,000 mg abiraterone acetate orally once daily in combination with 10 mg prednisone once daily until disease progression or unacceptable toxicity.

Patients receiving AKEEGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.

Take AKEEGA on an empty stomach at least one hour before or two hours after food. Swallow tablets whole with water. Do not break, crush, or chew tablets.

If a patient misses a dose, instruct patients to take the dose as soon as possible on the same day and resume their next dose at the normal schedule the following day.

The recommended dosage modifications for AKEEGA are provided in Table 1.

Treatment with AKEEGA should not be reinitiated until the toxicity has resolved to Grade 1 or baseline. If the toxicity is attributed to one component of AKEEGA, the other component of AKEEGA may be continued as a single agent at the current dose until the adverse reaction resolves and AKEEGA can be resumed .

Adverse Reaction | Severity | Dosage Modification

Myelosuppression

| Hemoglobin <8 g/dL | Withhold AKEEGA and monitor blood counts weekly.

When hemoglobin returns to ≥9 g/dL, resume at the reduced dose of AKEEGA 100 mg/1,000 mg once daily and monitor blood counts weekly for 28 days and as clinically indicated.

Permanently discontinue AKEEGA if hemoglobin has not returned to acceptable levels within 28 days of the dose interruption period or if the patient has already undergone dose reduction to 100 mg/1,000 mg once daily.

If myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) is confirmed, discontinue AKEEGA

.

Platelet count <100,000/mcL | First occurrence:

Withhold AKEEGA for a maximum of 28 days and monitor blood counts weekly until platelet counts return to ≥100,000/mcL.

Resume AKEEGA at same or the reduced dose of 100 mg/1,000 mg once daily.

If platelet count is <75,000/mcL, resume at the reduced dose of AKEEGA 100 mg/1,000 mg once daily. …

How to take Niraparib and Abiraterone — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hematologic Adverse Reactions

Advise patients that periodic monitoring of their blood counts is recommended. Advise patients to contact their healthcare provider for new onset of pallor, weakness, dyspnea, fatigue, bleeding, fever, or symptoms of infection

.

Hypokalemia, Fluid Retention, and Cardiovascular Adverse Reactions

Inform patients that AKEEGA is associated with, hypokalemia that may lead to QT prolongation. Advise patients that hypertension, hypokalemia, and fluid retention will be monitored at least weekly for the first two months, then once a month. Advise patients to adhere to corticosteroids and to report symptoms of hypokalemia or edema to their healthcare provider

.

Hepatotoxicity and Hepatic Impairment

Inform patients that AKEEGA is associated with severe hepatotoxicity. Inform patients that their liver function will be monitored using blood tests. Advise patients to immediately report symptoms of hepatotoxicity to their healthcare provider

.

Adrenocortical Insufficiency

Inform patients that AKEEGA with prednisone is associated with adrenal insufficiency. …

Warnings & precautions

Do not take this medicine if: None.

AKEEGA may cause myelodysplastic syndrome/acute myeloid leukemia (MDS/AML).

In the individual AMPLITUDE and MAGNITUDE studies, MDS or AML, including cases with fatal outcomes, were reported in 0.6% (2/347) and 0.5% (1/212) of patients treated with AKEEGA plus prednisone, respectively.

All patients in other tumor types treated with niraparib, a component of AKEEGA, who developed secondary MDS/cancer-therapy-related AML had received previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy.

For suspected MDS/AML or prolonged hematological toxicities, refer the patient to a hematologist for further evaluation. Discontinue AKEEGA if MDS/AML is confirmed.

AKEEGA may cause myelosuppression (anemia, thrombocytopenia, or neutropenia).

In AMPLITUDE, Grade 3–4 anemia, neutropenia, and thrombocytopenia were reported, respectively in 29%, 10%, and 4.9% of patients receiving AKEEGA. Overall, 25% of patients with anemia required a red blood cell transfusion, including 15% who required more than one transfusion. Discontinuation due to anemia occurred in 1.2% of patients.

In MAGNITUDE Cohort 1, Grade 3–4 anemia, thrombocytopenia, and neutropenia were reported, respectively in 28%, 8%, and 7% of patients receiving AKEEGA. Overall, 27% of patients with anemia required a red blood cell transfusion, including 19.5% who required more than one transfusion. Discontinuation due to anemia occurred in 3% of patients.

Monitor complete blood counts weekly during the first month of AKEEGA treatment, every two weeks for the next two months, monthly for the remainder of the first year and then every other month, and as clinically indicated. Do not start AKEEGA until patients have adequately recovered from hematologic toxicity caused by previous therapy. …

Niraparib and Abiraterone side effects

The following adverse reactions are discussed elsewhere in the labeling:

Myelodysplastic syndrome/acute myeloid leukemia

Myelosuppression

Hypokalemia, fluid retention, and cardiovascular adverse reactions

Hepatotoxicity

Adrenocortical insufficiency

Hypoglycemia

Increased fractures and mortality in combination with Radium 223 Dichloride

Posterior reversible encephalopathy syndrome

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety population described in the WARNINGS and PRECAUTIONS reflect exposure to AKEEGA (niraparib 200 mg and abiraterone acetate 1,000 mg) in

BRCA2m patients (N=162) in the AMPLITUDE study and in

BRCAm patients in Cohort 1 (N=113) in the MAGNITUDE study unless otherwise specified.

BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

The safety of AKEEGA in patients with

BRCA2m mCSPC was evaluated in AMPLITUDE

.

Patients were randomized to receive either AKEEGA (niraparib 200 mg and abiraterone acetate 1,000 mg once daily) (n=162), or placebo and abiraterone acetate (n=161) until unacceptable toxicity or progression. Patients in both arms also received prednisone 5 mg daily. The median duration of exposure for AKEEGA was 26 months (range: 0 to 48 months). …

Drug interactions

Effect of CYP3A4 Inducers

Avoid coadministration with strong CYP3A4 inducers

.

Abiraterone is a substrate of CYP3A4. Strong CYP3A4 inducers may decrease abiraterone concentrations

,

which may reduce the effectiveness of abiraterone.

CYP2D6 Substrates

Avoid coadministration unless otherwise recommended in the Prescribing Information for CYP2D6 substrates for which minimal changes in concentration may lead to serious toxicities. If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug.

Abiraterone is a CYP2D6 moderate inhibitor. AKEEGA increases the concentration of CYP2D6 substrates

,

which may increase the risk of adverse reactions related to these substrates.

CYP2C8 Substrates

Monitor patients for signs of toxicity related to a CYP2C8 substrate for which a minimal change in plasma concentration may lead to serious or life-threatening adverse reactions.

Abiraterone is a CYP2C8 inhibitor. AKEEGA increases the concentration of CYP2C8 substrates

,

which may increase the risk of adverse reactions related to these substrates.

About this medicine

AKEEGA

® (niraparib and abiraterone acetate) tablets contain niraparib tosylate (as the monohydrate) and abiraterone acetate.

Niraparib

Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. The chemical name for niraparib tosylate monohydrate is 2-{4-[(3S)-piperidin-3-yl]phenyl}-

2H-indazole 7-carboxamide 4-methylbenzenesulfonate hydrate (1:1:1). The molecular formula is C

26 H

30 N

4 O

5 S and it has a molecular weight of 510.61 g/mol. The molecular structure is shown below:

Niraparib tosylate monohydrate is a white to off-white, non-hygroscopic crystalline solid. Niraparib tosylate monohydrate is highly soluble in aqueous media over the pH range 1.2 to 6.8 (1.65–1.77 mg/mL determined at 37 ± 1°C).

Abiraterone Acetate

Abiraterone acetate is the acetyl ester of abiraterone. Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Its molecular formula is C

26 H

33 N O

2 and it has a molecular weight of 391.55 g/mol. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8245a990-3268-4613-b5c5-9537858a1eb9. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate